Compositions and methods for controlling carbohydrate and fat metabolism

1. A composition comprising at least:

a single extract obtained from a mixture of at least two plants selected from Chrysanthellum indicum, Cynara scolymus, Vaccinium myrtillus , Piper and Olea europaea,

and wherein the composition comprises:

at least one molecule, the at least one molecule being present in the single extract and/or added to the single extract, wherein the at least one molecule is selected from apigenin 7-O-glucuronide, chrysanthellin A, chrysanthellin B, caffeic acid, luteolin, maritimetin, eriodictyol, isookanin, apigenin, luteolin 7-O-glucoside, maritimein, marein, eriodictyol 7-O-glucoside, flavomarein, apigenin 8-C-α-L-arabinoside-6-C-β-D-glucoside (shaftoside), apigenin 6,8-C-di-β-D-glucopyranoside (vicenin-2), dicaffeoylquinic acid, sulfo-monocaffeoylquinic acid, luteolin 7-O-glucuronide, apigenin 7-O-glucoside, cynaropicrin, or analogs thereof,

at least one molecule, the molecule being present in the single extract and/or added to the single extract, wherein the at least one molecule is selected from a monocaffeoylquinic acid, delphinidin 3-galactoside, delphinidin 3-glucoside, cyanidin 3-galactoside, delphinidin 3-arabinoside, cyanidin 3-glucoside, petunidin 3-galactoside, cyanidin 3-arabinoside, petunidin 3-glucoside, peonidin 3-galactoside, petunidin 3-arabinoside, peonidin 3-glucoside, malvidin 3-galactoside, malvidin 3-glucoside, malvidin 3-arabinoside, or analogs thereof, and

wherein the composition also comprises at least one molecule selected from oleuropein, hydroxytyrosol, and analogs thereof; and wherein the single extract is not obtained from a mixture of five plants: Chrysanthellum indicum, Cynara scolymus, Vaccinium myrtillus , Piper and Olea europaea.

2. The composition of claim 1 , wherein the composition further comprises at least one of the following extracts:

one extract of Chrysanthellum indicum , if the mixture of plants in the single extract of claim 1 does not comprise Chrysanthellum indicum,

one extract of Cynara scolymus , if the mixture of plants in the single extract of claim 1 does not comprise Cynara scolymus,

one extract of Vaccinium myrtillus , if the mixture of plants in the single extract of claim 1 does not comprise Vaccinium myrtillus,

piperine or an extract of Piper, if the mixture of plants in the single extract of claim 1 does not comprise Piper, and/or

one extract of Olea europaea , if the mixture of plants in the single extract of claim 1 does not comprise Olea europaea.

3. The composition of claim 1 , wherein the composition comprises dicaffeoylquinic acid, apigenin 7-O-glucuronide, a monocaffeoylquinic acid, piperine and oleuropein.

4. The composition of claim 1 , wherein the Piper plant is selected from Piper nigrum, Piper aduncum and Piper longum.

5. The composition of claim 1 , wherein the mixture comprises Chrysanthellum indicum whole plant and/or aerial parts.

6. The composition of claim 1 , wherein the mixture comprises Cynara scolymus whole plant and/or leaves.

7. The composition of claim 1 , wherein the mixture comprises Vaccinium myrtillus whole plant and/or fruit.

8. The composition of claim 1 , wherein the mixture comprises Olea europaea leaves and/or fruit.

9. The composition of claim 1 , wherein the composition is in the form of tablets, wafer capsules, gel capsules, sticks, sachets, vials, droppers or in injectable form.

10. The composition of claim 1 , wherein the composition also comprises at least one additional element added to the mixture of molecules, said additional element being selected from:

the following vitamins: B1, B2, B3, B5, B6, B8, B9, B12 C, A, D, E, K1, K2 or any combination thereof;

the following compounds: obeticholic acid, corosolic acid, polyunsaturated fatty acids of the omega 6 and/or omega 3 family, orotic acid, pangamic acid, para-aminobenzoic acid, amygdalin, beta-glucans, carnitine, dimethylglycine, imeglimin, isoflavones, L-arginine, oxytocin, pectin, pyridoxamine, resveratrol, viniferin, L-citrulline, or any combination thereof;

the following trace elements and minerals: arsenic, boron, calcium, copper, iron, fluorine, iodine, lithium, manganese, magnesium, molybdenum, nickel, phosphorus, selenium, vanadium, zinc, or any combination thereof;

the following microconstituents of non-essential nature: conjugated linolenic acid, lipoic acid, carotenoids, carnitine, choline, coenzyme Q10, phytosterols, polyphenols of the tannin and lignan family, taurine, or any combination thereof;

fructo-oligosaccharides, galacto-oligosaccharides, or any combination thereof;

lactic acid-fermenting bacteria;

yeasts;

mushroom;

products derived from insects that are compatible with the food and pharmaceutical sector;

marijuana and haschisch;

the following coating agents: hypromellose, microcrystalline cellulose, stearic acid, talc, sucrose, shellac, povidone, beeswax;

the following flavors: natural flavor of blueberry or natural flavor of strawberry;

the following acidifying agents: malic acid;

the following antiagglomerating agents: silicon dioxide or magnesium stearate;

the following thickeners: xanthan gum, colloidal silica, fatty acid mono- and diglycerides;

the following stabilizers: calcium phosphate;

the following emulsifiers: soybean lecithin;

the following fillers: s corn starch;

excipients selected from the group consisting of: microcrystalline cellulose, magnesium stearate and dicalcium phosphate.

11. The composition of claim 1 , wherein the composition is formulated as a nutrition product and/or medicament for preventing and/or treating pathological disorders of carbohydrate and/or fat metabolism in humans or animals.

12. A method of treatment for a pathological disorder in human and animal patients, the method comprising administering to the patient the composition of claim 1 .

13. The method of claim 12 , wherein the pathological disorder is selected from the group consisting of type 1 diabetes, type 2 diabetes, a non-alcoholic fatty liver disease, a cardiovascular pathology, a pathology associated with insulin resistance in a patient, and any combination thereof.

14. The method of claim 13 , wherein the non-alcoholic fatty liver disease is non-alcoholic steatohepatitis.

15. The method of claim 13 , wherein the cardiovascular pathologies are coronary cardiopathies, cerebrovascular diseases, peripheral arteriopathies, and/or deep vein thromboses.

16. The method of claim 13 , wherein the pathology associated with insulin resistance is Alzheimer's disease.

17. The method of claim 13 , wherein the method further comprises administering at least one antidiabetic therapeutic agent chosen from biguanides including metformin, dipeptidyl peptidase-IV (DPP-IV) inhibitors, glucagon-like peptide-1 (GLP-1) analogs, thiazolidinediones (TZDs), sulfonylureas, rapid and slow insulins, sodium glucose co-transporter-2 (SGLT2) inhibitors, glycosidase inhibitors, acarbose, miglitol, voglibose, peptides containing the alanine-proline or proline-alanine sequence, molecules of the fibranor family, elafibranor, or molecules targeting ROR (α, β, γ) receptors and Rev-Erb (α, β) receptors.

18. The method of claim 12 , wherein the pathological disorder is dyslipidemia.

19. The method of claim 13 , wherein the method further comprises administering a hypolipemiant therapeutic agent chosen from: statins, fibrates, nicotinic acid, ion-exchange resins, cholesterol absorption inhibitors, omega 3 polyunsaturated fatty acids, tiadenol, and FXR (Farnesoid X Receptor) nuclear receptor agonists.

20. The method of claim 12 , wherein the pathological disorder is obesity and excess weight and/or metabolic syndrome and/or pathological problems of arterial tension.